Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Abstract 117: RhoC Regulates VEGF-induced Signaling in Endothelial Cells
Dutta, Shamit K., Suresh, Sandip , Chun, Chang Zoon, Hoeppner, Luke H. , Sinha, Sutapa , Wang, Ying , Bhattacharya, Resham , Gong, Xun , Bedell, Victoria M. , Ramchandran, Ramani , Ekker, Stephen C. , Mukhopadhyay, Debabrata

Mayo Clinic

Circulation Research | July 3, 2021 | Volume: 115 | Issue: suppl_1 | Pages: No page available

10.1161/res.115.suppl_1.117 Get It

Vascular permeability factor/vascular endothelial growth factor A (VEGF) is a central regulator of angiogenesis and potently promotes vascular permeability. VEGF plays a key role in the pathologies of heart disease, stroke, and cancer. Therefore, understanding the molecular regulation of VEGF signaling is an important pursuit. Rho GTPase proteins play various roles in vasculogenesis and angiogenesis. While the functions of RhoA and RhoB in these processes have been well defined, little is known about the role of RhoC in VEGF-mediated signaling in endothelial cells and vascular development. Here, we describe how RhoC modulates VEGF signaling to regulate endothelial cell proliferation, migration and permeability. We found VEGF stimulation activates RhoC in human umbilical vein endothelial cells (HUVECs), which was completely blocked after VEGF receptor 2 (VEGFR-2) knockdown indicating that VEGF activates RhoC through VEGFR-2 signaling. Interestingly, RhoC knockdown delayed the degradation of VEGFR-2 compared to control siRNA treated HUVECs, thus implicating RhoC in VEGFR-2 trafficking. In light of our results suggesting VEGF activates RhoC through VEGFR-2, we sought to determine whether RhoC regulates vascular permeability through the VEGFR-2/phospholipase Cγ (PLCγ) /Ca 2+ /eNOS cascade. We found RhoC knockdown in VEGF-stimulated HUVECs significantly increased PLC-γ1 phosphorylation at tyrosine 783, promoted basal and VEGF-stimulated eNOS phophorylation at serine 1177, and increased calcium flux compared with control siRNA transfected HUVECs. Taken together, our findings suggest RhoC negatively regulates VEGF-induced vascular permeability. We confirmed this finding through a VEGF-inducible zebrafish model of vascular permeability by observing significantly greater vascular permeability in RhoC morpholino (MO)-injected zebrafish than control MO-injected zebrafish. Furthermore, we showed that RhoC promotes endothelial cell proliferation and negatively regulates endothelial cell migration. Our data suggests a scenario in which RhoC promotes proliferation by upregulating -catenin in a Wnt signaling-independent manner, which in turn, promotes Cyclin D1 expression and subsequently drives cell cycle progression.
Abstract 120: Identification Of A Novel Adult Smooth Muscle-like Stem/progenitor Cell That Facilitates Formation Of Tissue Engineered Vascular Tissue For Use As Vascular Grafts In Vivo
Turner, Elizebeth C., Huang, Chien Ling, Sawhney, Neya, Govindarajan, Kalai, Clover, James P., Martin, Kenneth, Wang, Sharon X. , Kumar, Arun , Clover, A. James P. , Leblond, Anne‐Laure , Wang, Sharon, Caplice, Noel M.

Mayo Clinic

Circulation Research | July 3, 2021 | Volume: 113 | Issue: suppl_1 | Pages: No page available

10.1161/res.113.suppl_1.a120 Get It

The aim of this study was to characterise a recently identified adult smooth muscle stem-like/progenitor cell (SMSPC) and exploit the ability to differentiate contractile smooth muscle cells (SMC) from SMSPCs facilitating tissue engineering of small to medium arteries, an approach which is hampered by inadequate sources of, and scale up methodologies for autologous SMCs. We initially identified a novel SMSPC in the bone marrow (BM) of rats that retained classic stem cell-like characteristics (clonogenicity, unlimited self-renewal, high telomerase activity, expression of stem cell markers) whilst expressing low levels of SMC-like transcripts. Spontaneous differentiation favoured a SMC phenotype where ~20-fold increases in calponin and SM-MHC protein expression were observed 10 days post-embryoid body formation, an effect augmented by TGFβ (P < 0.0001). Differentiation of SMSPCs from an undifferentiated state towards contractile SMCs was Myocd-dependent. Overexpression of Myocd in SMSPCs increased their percentage contraction in response to AngII (P < 0.05) and KCL (P < 0.05) and Ca2+ signalling to levels indistinguishable from rat SMCs. Knockdown of SMC-specific repressors resulted in Myocd-dependent SMC differentiation of SMSPCs. Taking advantage of the fact that SMSPCs possessed unlimited self-renewal capacity ex vivo and could be successfully reprogrammed into functional SMCs, we determined the vascular tissue engineering potential of SMSPCs and showed these cells integrate as viable tissue engineered vascular grafts in vivo. Specifically, after 1 month implantation, a Myocd-GFP+/Isl1+ smooth muscle layer was observed in the grafts along with a vWF+ luminal endothelial layer and multi-layered collagen and elastin fibre formation throughout the graft wall. We have recently isolated cells with similar SMSPC phenotype and differentiation potential from human peripheral blood. This study demonstrates that adult SMSPCs derived from rat BM and human blood can be reprogrammed to efficiently generate large quantities of mature contractile SMCs, displaying great utility as a cellular backbone for tissue engineered vascular grafts, making them an attractive source for vascular cell therapy and surgical applications.
Abstract 118: Are Patients with Atherosclerotic Cardiovascular Disease Receiving Appropriate Lipid Management? Insights from the PALM Registry
Robinson, Jennifer G. , Goldberg, Anne C. , Roger, Véronique L. , Elassal, Joseph, Lee, L. Veronica, Wang, Tracy Y , Návar, Ann Marie , Peterson, Eric D. , Li, Shuang, Virani, Salim S. , Wilson, Peter W.F.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 9 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.9.suppl_2.118 Get It

Background: Prior ATPIII lipid guidelines recommended statin therapy for patients with clinical ASCVD to achieve low density lipoprotein cholesterol (LDL-C) targets, while the 2013 ACC/AHA lipid guidelines recommend high-intensity statin therapy for all ASCVD patients. How closely these recommendations are followed in routine clinical practice is unknown. Methods: We evaluated statin use, intensity, and LDL-C values in 1,483 patients with ASCVD (coronary heart disease, cerebrovascular disease, and peripheral arterial disease) enrolled and seen serially at 62 geographically dispersed US cardiology and primary care clinics in the Patient and Provider Assessment of Lipid Management (PALM) Registry between May - September 2015. Factors associated with high intensity statin use (atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) and LDL-C <70 mg/dL were evaluated in multivariable logistic regression. Results: Of 1,483 ASCVD patients, 86.2% were on a statin, but only 31.4% were on a high-intensity statin. Overall, 64.0% had an LDL-C <100 mg/dL, but only 29.0% had an LDL-C <70 mg/dL. Factors associated with high-intensity statin use in multivariable regression were younger age (OR 0.74 per 10 year increase, p<0.001, 95% CI 0.66-0.83), male sex (OR 1.69, p<0.001, 95% CI, 1.32-2.16), cerebrovascular disease (OR 1.55, p=0.008, 95% CI 1.12-2.13), coronary heart disease (OR 2.42, p<0.001, 95% CI 1.67-3.50), and being seen by a cardiologist (OR 1.35, p =0.04, 95% CI 1.01-1.81). Factors associated with an increased likelihood of LDL-C<70 were male sex (OR 1.55, p=0.001, 95% CI 1.20-2.01), white (OR 1.62, p=0.03, 95% CI 1.04-2.5-, diabetes (OR 1.64, p<0.001, 95% CI 1.29-2.09) and being seen by a cardiologist (OR 1.94, p<0.001, 95% CI 1.41-2.67). Discussion: Substantial gaps in care remain for secondary prevention of ASCVD despite simplified recommendations. While the majority of patients with ASCVD in community practice are on a statin, only one-third are on high intensity statins and over two-thirds have LDL ≥70 mg/dL.
Abstract 236: Trends in Hospitalization for Digoxin Toxicity and Subsequent Outcomes Among Medicare Beneficiaries in the United States, 1999-2011
Nuti, Sudhakar V., Masoudi, Frederick A. , Shah, Nilay D. , Wang, Yun , Freeman, James V. , Murugiah, Karthik , Desai, Nihar R. , Ranasinghe, Isuru , Krumholz, Harlan M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.236 Get It

Objective: To characterize changes in rates of hospitalization for digoxin toxicity and trends in the associated mortality and readmission among older adults over a 12-year period in the United States. Methods: We studied 33,952,331 Medicare fee-for-service beneficiaries 65 years or older with a hospital discharge diagnosis of digoxin toxicity in the United States from 1999 to 2011. Outcome measures were rates of hospitalization for digoxin toxicity; in-hospital mortality; 30-day mortality; and 30-day readmission. Results: There were 20,957 hospitalizations for a principal or secondary diagnosis of digoxin toxicity between 1999 and 2011. The rate declined significantly from 15.2 per 100,000 person-years (95% confidence interval [CI]: 14.7-15.7) in 1999 to 2.1 per 100,000 person-years (95% CI: 1.9-2.3) in 2011 (p<0.001), representing an adjusted annual decline of 17.0% (95% CI: 16.2-17.0) (Figure 1). Between 1999 and 2011, the observed in-hospital and 30-day mortality rates associated with hospitalization for digoxin toxicity declined significantly, from 6.0% (95% CI: 5.2-6.8) to 3.3% (95% CI: 2.0-5.1) (p<0.01) and 14.0% (95% CI: 13.0-15.2) to 10.6% (95% CI: 8.2-13.4) (p<0.05), respectively, representing an annual decline for in-hospital mortality of 5.0% (95% CI: 3.7-7.2) and for 30-day mortality of 4.0% (95% CI: 3.1-5.7). The overall observed 30-day readmission rate declined significantly from 23.5% (95% CI: 22.1-24.9) in 1999 to 18.9% (95% CI: 15.6-22.3) in 2011 (p<0.05), but there was no significant decline in the adjusted annual change in 30-day readmission (1.0%, 95% CI: 0.0-1.7). Conclusions: In a national sample of Medicare beneficiaries, the rate of hospitalization for digoxin toxicity and subsequent mortality declined significantly between 1999 and 2011.
Abstract 309: Is Right Bundle Branch Block Associated with Poor Outcomes in the Setting of an Acute Coronary Syndrome? A Systematic Review and Meta-analysis
Hazem, Ahmad, Sharma, Sunita , Sharma, Amit , Leitch, Cameron, Sharadanant, Roopalakshmi, Uriell, Matthew, Neutzling, Kari, Moreno, Patricia Brrionuevo, Sorita, Atsushi , Vilesnki, Leonid, Makkuni, Premraj, Ting, Henry H. , Wang, Zhen , Moreno, Patricia Barrionuevo, LeBlanc, Annie , Prokop, Larry J. , Murad, M. Hassan

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.309 Get It

Importance: Up to 10% of patients with acute myocardial infarction (AMI) have right bundle branch block (RBBB), and RBBB has been associated with a higher risk of mortality. We performed a systematic review and meta-analysis to determine the prognostic significance of RBBB for patients with AMI. Acute coronary syndrome (ACS) Data Sources: We have systematically searched Ovid, Scopus and Web of Science through January 2014. Study Selection: Reviewers working independently and in duplicate screened all eligible abstracts, selecting studies that described all-cause mortality or cardiovascular death in patients with RBBB and suspected ACS. We excluded studies that reported unadjusted outcomes. Knowledge synthesis: We pooled risk ratio with hazard ratio in studies reporting those outcomes. When reported, odds ratio was converted into risk ratio using reported event rate in each study’s unexposed -read: non RBBB- group. Main Outcomes: All-cause mortality and cardiovascular mortality (death). Results: Eighteen studies were found that reported eligible data. All were observational studies, involving over 89,000 patients. In short-term follow up (up to 30 days), RBBB on presentation was associated with higher all-cause mortality rate, compared to patients without RBBB (RR 2.23, 95% CI 1.76-2.82). There was a trend for higher mortality at long-term follow up (range: 6 months-16 years) that did not reach statistical significance (RR 1.45, 95% CI 0.93-2.25). Figure-1 demonstrates the forest plot. Risk of bias was assessed with the Newcastle-Ottawa scale and majority of included studied were deemed moderate to high quality. Conclusion and Relevance: RBBB is associated with a more than 2-fold higher risk of all-cause mortality in patients with AMI at 30 days follow up. Patients with AMI and RBBB represent a high risk group for adverse outcomes. A sentence on the differential findings for new vs. old RBBB and association with outcomes could follow here.
Abstract 118: Right Bundle Branch Block and Clinical Outcomes in Patients with Heart Failure: A Systematic Review and Meta-analysis
Hazem, Ahmad, Sharma, Sunita , Sharma, Amit , Leitch, Cameron, Sharadanant, Roopalakshmi, Uriell, Matthew, Neutzling, Kari, Moreno, Patricia Barrionuevo, Sorita, Atsushi , Vilenski, Leonid, Prokop, Larry, Makkuni, Premraj, Ting, Henry H. , LeBlanc, Annie , Wang, Zhen , Murad, M. Hassan

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.118 Get It

Importance: Right bundle branch block (RBBB) is observed in approximately 5-14% of patients with heart failure (HF). Multiple observational studies have reported the association of RBBB with clinical outcomes in patients with HF. We performed a systematic review and meta-analysis to determine the prognostic significance of RBBB for patients with HF. Data Sources: We have systematically searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus through January 2014. Study Selection: Reviewers working independently and in duplicate screened all eligible abstracts that described all cause or cardiovascular mortality in patients with RBBB and HF. We excluded studies that reported unadjusted outcome, i.e.: unadjusted event rates. Knowledge synthesis: We pooled reported risk ratio and hazard ratio. Main Outcomes: All-cause mortality and cardiovascular mortality (death). Results: We found 12 relevant observational studies enrolling over 38,000 patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Included studies had at least a moderate quality. Seven of those evaluated prognosis of patients with RBBB and heart failure. After a mean follow up period of 2.5 years (range: 1-5 years), RBBB was associated with a statistically significant increased risk of all-cause mortality compared to patients with heart failure but no BBB, RR 1.27, 95% CI (1.08-1.50), Figure 1. The other 5 studies evaluated CHF patients receiving cardiac resynchronization therapy (CRT), comparing outcomes of patients with RBBB to those with LBBB. After a mean f/u period of 3 years, patients with RBBB were once again found to have an increased risk of all-cause mortality, RR 1.45, 95% CI 1.12-1.89. Conclusion and Relevance: RBBB in patients with HF is associated with higher all-cause mortality in comparison to patients without inter-ventricular conduction defects, as well as LBBB patients in patients undergoing CRT setting.
Abstract 19392: A Landmark Analysis of 30-day Mortality after Coronary Artery Bypass Surgery in Patients with Ischemic Heart Failure: Results of the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
Stevens, Susanna R., Jones, Robert H., Beaver, Thomas M. , Djokovic, Ljubomir T., DiMaio, Micheal J, Michler, Robert E. , Lee, Kerry L., Yii, Michael, Chua, Yeow Leng , Zembala, Marian, Rouleau, Jean L. , Al‐Khalidi, Hussein R. , Daly, Richard C. , Wróbel, Krzysztof , Selzman, Craig H. , Lamy, Andre L. , Wang, Nan, Velazquez, Eric J. , Sopko, George S. , Kron, Irving Louis , DiMaio, M.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.19392 Get It

Background: Among patients (pts) with coronary artery disease (CAD) who are candidates for coronary artery bypass graft surgery (CABG), a reduced ejection fraction (EF) identifies a high-risk group. The profile of pre-operative, intra-operative and post-operative factors contributing to 30 day (d) mortality in pts with low EF undergoing CABG has not been well characterized. Methods: The STICH trial enrolled 2136 pts with CAD amenable to CABG with an LVEF < 35% who were treated with medical therapy (MED) alone, MED with CABG, or with MED plus CABG and surgical ventricular resconstruction (SVR). Multivariable logistic regression models utilizing extensive baseline, intra-operative and post-operative care variables were developed to determine factors associated with mortality at 30d in a landmark analysis among pts surviving the first 36 hours (h). Results: Among those enrolled, 1460 pts received CABG; 673 (46.1%) on pump, 160 (11.0%) off pump, 132 (9.0%) with a mitral valve procedure (MVR), 393 (26.9%) with SVR, and 102 (7.0%) received CABG with SVR and MVR. Mortality in the operating room (OR) was 0.3 %, within the first 36h was 1.0%, and at 30d was 5.1%. The rate of in-hospital acute myocardial infarction was 0.8%, stroke 1.6%, mediastinitis 1.7%, worsening renal insufficiency 8.4%, and return to OR was 6.9%. Inotropes were used in 43.6% and intra-aortic balloon pump in 18.6%. At 36h, 148 pts (10.2%) remained intubated. Among pts who survived to 36h, a robust multivariable model (Table, c-statistic 0.89) was developed to predict 30d mortality. A prolonged intubation time (>36h) was the strongest marker of 30d mortality (odds ratio 7.4, 95% CI 3.8, 14.5, p<0.0001). Conclusions: Among pts with ischemic heart failure, CABG can be performed with a low rate of complications and intra-operative mortality. Prolonged intubation time (>36h) after CABG is an integrated clincal marker that may serve to identify those pts with the least likelihood of survival to 30d.
Abstract 17218: Reduced Left Atrial Compliance in Heart Failure With Preserved Ejection Fraction: New Insights Into Pathophysiology
Chai, Qiang , Ogut, Ozgur, Takahama, Hiroyuki , Lu, Tong , Wang, Xiaoli , Lee, Hon-Chi , Redfield, Margaret M. , Zakeri, Rosita , Chai, Qiang, Moulay, Gilles , Hussain, Saad, Linke, Wolfgang A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.17218 Get It

Background: Reduced left atrial (LA) compliance (LAC) contributes to pulmonary venous hypertension in heart failure with preserved ejection fraction (HFpEF); however the underlying mechanisms are poorly defined. We hypothesized that microvascular inflammation with rarefaction and impaired nitric oxide (NO) signaling, LA titin hypophosphorylation and fibrosis may each contribute to reduced LAC in HFpEF. Methods: Invasive LA pressure-volume (PV) analyses (open-chest; pericardiotomy; admittance catheter) were performed in 9 aged dogs with experimental hypertension (bilateral renal wrap + DOCA; HFpEF) compared to 13 sham-operated young adult dogs (control). LAC was measured at end-LA reservoir during acute preload reduction (cava occlusion). LA tissue and LA microvascular function were analyzed. Results: Compared to controls, the curvilinear end-LA reservoir PV relationship ( Fig A ) was shifted upward/leftward in HFpEF (LA diastolic stiffness constant 0.08 vs 0.16 mmHg/mL in controls, p=0.005). LA microvascular density (MVD; CD31 stain) tended to be lower in HFpEF than controls (2154±578 vs 2650±523 vessels/mm 2 , p=0.07) and LA MVD negatively correlated with the LA diastolic stiffness constant (r=-0.66, p=0.006). LA microvessels from HFpEF dogs showed impaired endothelium-dependent shear stress-mediated dilation compared to controls, consistent with impaired NO signaling ( Fig B ). Titin isoform expression was similar between groups, but isoform N2B (stiffer) was (p=0.03) and N2BA (compliant) tended to be (p=0.09) hypophosphorylated in HFpEF LA appendage (LAA) tissue. Fibrosis (Picrosirius Red) was similar between groups in the LA free wall and LAA, but increased in areas adjacent to the pulmonary veins in HFpEF (27±12% vs controls 15±8%, p=0.01). Conclusion: In experimental HFpEF, LAC was reduced in association with evidence of LA microvascular rarefaction and impaired NO signaling, titin hypophosphorylation and regional increases in LA fibrosis.
Abstract 13189: CV-Ecosystem Model: Workplace Wellness With Individualized Medicine
Krittanawong, Chayakrit , Kermott, Cindy A. , Zhang, Hongju, Marysia, Tweet S, Wang, Zhen , Chirapongsathorn, Sakkarin , Hayes, Sharonne N.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13189 Get It

Introduction: At-work stress is rapidly becoming a significant contributory cause of occupational disease, while sedentary work and dietary indiscretion, taken together, have contributed to cardiovascular disease, known to be associated with substantial morbidity and mortality. The aim of the CV-Ecosystem Model is to provide an individual approach by systematic environmental modification of the work site. Methods and Results: Our model which we term the CV-Ecosystem Model includes two basic tenets: 1) Workstation technologic design 2) Flexible physiologic activity. Workstation technologic design utilizes the services of a certified Ergonomist to engineer a comfortable, safe, and effective work environment. It is tailored to the unique physiologic needs of the worker while enhancing productivity within different environments. Computer aided design software would evaluate ergonomics to maximally mitigate the risk and incidence of eye strain, musculoskeletal disorders, repetitive movement disorders such as Carpal Tunnel Syndrome, etc unique to that work activity. Flexible physiologic activity would permit a worker to actively focus on basic needs during work time, on site; this would include exercise activity and food intake, channeled into healthy options. Exercise time would provide a sense of calm during stressful projects and enhance emotional well-being. In this regard, a three hour period of time, weekly, could be allocated to fitness or meditation. Conveniently located food stations could provide a variety of healthy, plant-based, fresh food options. Both would come with flexible, relative control and scheduling of these activities, within a social environment and context. Conclusions: The CV Ecosystem Model, due to its simple technology and relative low cost, could be successfully implemented in a number of enterprises, including all healthcare facilities, with benefit to employee health, wellbeing, and favorable to the business bottom line.
Abstract P020: Associations of Markers of Inflammation with Nocturnal BP Dipping Status Using Two Common Dipping Definitions: the Genetic Epidemiology Network of Arteriopathy
To, Harrison, Wang, Wanmei, Windham, B. Gwen, SCHWARTZ, G, Griswold, Michael , Mosley, Thomas H. , Turner, Stephen T. , Schwartz, Gary L. , Kullo, Iftikhar J. , Butler, Kenneth R.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 129 | Issue: suppl_1 | Pages: No page available

10.1161/circ.129.suppl_1.p020 Get It

Background: Compared to those with natural nocturnal blood pressure (BP) decreases, those lacking nocturnal BP decreases (“non-dippers”) are at greater risk of cardiovascular disease (CVD). Substantial evidence also supports a role of chronic systemic inflammation in the pathogenesis of CVD. The purpose of this study was to examine associations of markers of inflammation with two common definitions of BP dipping status using 24-hour ambulatory blood pressure (AMBP) readings. Methods: AMBP monitoring and assays of C-reactive protein (CRP), interleukin-6 (IL-6), e-selectin, tissue inhibitor of metalloproteinase-2 (TIMP-2), and a selection of thirteen other inflammatory-pathway biomarkers were performed in 722 participants (mean age 64 [range 42-83] years, 36% men, 39% black, 83% hypertensive) in the Genetic Epidemiology Network of Arteriopathy (GENOA) Study (2001-2004). Non-dippers were classified using two common definitions: (1) nocturnal systolic and diastolic BP both decreased by <10% compared to daytime values [“dual non-dippers”, n=161 (22%)], and (2) nocturnal SBP decreased by <10% [“systolic non-dippers”, n=380 (53%)]. Logistic regressions, fit with generalized estimating equations to account for sibship clustering, yielded odds ratios (OR) of dipping status for log-transformed inflammatory biomarkers, adjusted for age, race, and sex. Results: IL-6 (range 0-37 pg/ml) was associated with dual non-dipping status (OR=1.55 [95%CI: 1.03, 2.32] p=0.035), translating into a 55% increase in the likelihood of being a dual non-dipper for every approximate doubling of IL-6. IL-6 (OR=1.63 [1.13, 2.35] p=0.009) and CRP (OR=1.35 [1.08,1.68] p=0.008) overall, as well as e-selectin (OR=0.49 [0.28, 0.87] p=0.014) and TIMP-2 (OR=0.54 [0.30,0.98] p=0.041) in hypertensive subjects were associated with systolic non-dipping status. Conclusions: These results suggest that non-dipping classification should be approached with prudence, as the two different criteria may influence conclusions about predictive marker associations. In addition, markers involved in direct versus inhibitory inflammation pathways may operate differentially across patient subgroups. Our findings support the link between inflammation and non-dipping circadian BP patterns and provide novel information on markers and definitions which may be useful for early detection and subsequent prevention of CVD.